Anti-IDH1 R132H (Hu) from Mouse (H09)
- Images (7)
| Article Name: | Anti-IDH1 R132H (Hu) from Mouse (H09) |
| Biozol Catalog Number: | DNA-DIA-H09 |
| Supplier Catalog Number: | DNA-DIA-H09 |
| Alternative Catalog Number: | DNA-DIA-H09 |
| Manufacturer: | dianova |
| Host: | Mouse |
| Category: | Antikörper |
| Application: | IHC |
| Species Reactivity: | Human |
| Immunogen: | Synthetisches Peptid, Aminosauresequenz CKPIIIGHHAYGD |
| Conjugation: | Unconjugated |
| Alternative Names: | IDH1,Isocitrate dehydrogenase [NADP] (cytoplasmic),PICD,IDP,Oxalosuccinate decarboxylase,NADP(+)-specific ICDH,Cytosolic NADP-isocitrate dehydrogenase,Isocitrate Dehydrogenase 1, Soluble, ATRXBundle |
| Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. |
The 2016 CNS WHO classification recommends IDH1 R132H IHC as a backbone for differential diagnosis of glioma. IDH1 R132H IHC is widely applied as a favorable prognostic marker.
ReactivityAntibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor specimens. Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis. This antibody is highly useful for tumor classification and in detecting single infiltrating tumor cells. The routine practical approach for diagnosing astrocytomas and oligodendrogliomas begins with perfoming IHC for IDH1 R132H and ATRX expression (Reuss et al., 2015). Instructions for UseImmunohistochemical staining of standard formalin-fixed paraffin sections Deparaffinize and rehydrate according to standard procedures. Heat induced epitope retrieval (HIER) is required. For immunohistochemical detection different techniques can be used: Indirect immunoenzyme labeling with a secondary antibody conjugate, biotin/(strept)avidin-based detection, soluble enzyme immune complex or polymer-based detection. To detect antibody, follow the instructions provided with the particular visualization system. The antibody is suited for immuno-histochemical staining using automated platforms. Use the antibody at 1:20-1:100 dilution for 30min at RT. Technical note Diffuse astrocytoma WHO grade II may have low protein-expression. At high dilution of the antibody single tumor cells in the infiltration zone may not be stained (recommended dilution 1:20). Intented use / regulatory statusEurope: For in Vitro Diagnostic Use / All other countries: For Research Use only |
| Application Dilute: | Histo-/Zytochemie 1:20 - 1:100,Western Blot (WB): 1:500 |
|
|
IDH1 R132H: infiltration zone glioma |
|
|
IDH1 R132H: Cortex infiltrated by oligodendroglioma |
|
|
IDH1 R132H: Double staining of GFP and clone H09 |
|
|
IDH1 R132H: Identification of single tumor cells |
|
|
IDH1 R132H: infiltrating glioma cells |
|
|
IDH1 R132H: strong reaction on mutated diffuse astrocytoma |
|
|
IDH1 R132H: tumor center of anaplastic oligoastrocytoma. |
